BIIB stock forecast
Our latest prediction for Biogen, Inc.'s stock price was made on the May 1, 2019 when the stock price was at 229.50$.
In the short term (2weeks), BIIB's stock price should outperform the market by 2.87%. During that period the price should oscillate between -5.07% and +7.93%.
In the medium term (3months), BIIB's stock price should underperform the market by -0.78%. During that period the price should oscillate between -12.69% and +17.81%.Get email alerts
Create a solid portfolio with BIIB
About Biogen, Inc.
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
At the moment the company generates 13812M USD in revenues.
On its last earning announcement, the company reported a profit of 23.19$ per share.
The book value per share is 60.87$
Three months stock forecastMay 1, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|